Middle ear neuroendocrine tumor

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Feb 2017

Xermelo: FDA approved

Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Middle ear neuroendocrine tumor.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Xermelo

(telotristat etiprate)Orphan drug

TerSera Therapeutics, LLC

12.1 Mechanism of Action Telotristat, the active metabolite of telotristat ethyl, is an inhibitor of tryptophan hydroxylase, which mediates the rate l...

Approved Feb 2017FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Middle ear neuroendocrine tumor.
Search all trials →
Search clinical trials for Middle ear neuroendocrine tumor

Recent News & Research

No recent news articles indexed yet for Middle ear neuroendocrine tumor.
Search PubMed for Middle ear neuroendocrine tumor

Browse all Middle ear neuroendocrine tumor news →

Specialist Network

No specialists currently listed for Middle ear neuroendocrine tumor.

View all Middle ear neuroendocrine tumor specialists →

Quick Actions